These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10668603)

  • 41. Recreational ecstasy use and depression.
    Guillot C; Greenway D
    J Psychopharmacol; 2006 May; 20(3):411-6. PubMed ID: 16574715
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MDMA (Ecstasy) use and psychiatric problems.
    Guillot CR; Berman ME
    Psychopharmacology (Berl); 2007 Jan; 189(4):575-6. PubMed ID: 17061108
    [No Abstract]   [Full Text] [Related]  

  • 43. Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug.
    Camarasa J; Pubill D; Escubedo E
    Brain Res; 2006 Sep; 1111(1):72-82. PubMed ID: 16889759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [MDMA ("Ecstasy") use--an overview of psychiatric and medical sequelae].
    Thomasius R; Schmolke M; Kraus D
    Fortschr Neurol Psychiatr; 1997 Feb; 65(2):49-61. PubMed ID: 9157047
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Abuse of Ecstasy (3,4-methylenedioxymethamphetamine). Pharmacological, neuropsychiatric and behavioral aspects].
    Nielsen JC; Nicholson K; Pitzner-Jørgensen BL; Undén M
    Ugeskr Laeger; 1995 Feb; 157(6):724-7. PubMed ID: 7701630
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comment on R. Thomasius, M. Schmolke, D. Kraus: MDMA ("Ecstasy") use--an overview of psychiatric and medical sequelae].
    Gouzoulis-Mayfrank E; Hermle L; Kovar KA; Sass H
    Fortschr Neurol Psychiatr; 1999 Dec; 67(12):574-6. PubMed ID: 10683753
    [No Abstract]   [Full Text] [Related]  

  • 47. Neurological and cognitive alterations induced by MDMA in humans.
    Montgomery C; Roberts CA
    Exp Neurol; 2022 Jan; 347():113888. PubMed ID: 34624331
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The "ecstasy" hangover: hyponatremia due to 3,4-methylenedioxymethamphetamine.
    Traub SJ; Hoffman RS; Nelson LS
    J Urban Health; 2002 Dec; 79(4):549-55. PubMed ID: 12468674
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebrovascular accident following MDMA ingestion.
    Muntan CD; Tuckler V
    J Med Toxicol; 2006 Mar; 2(1):16-8. PubMed ID: 18072107
    [No Abstract]   [Full Text] [Related]  

  • 50. Malignant hyperpyrexia in an MDMA ("Ecstasy") abuser.
    McCoy EP; Renfrew C; Johnston JR; Lavery G
    Ulster Med J; 1994 Apr; 63(1):103-7. PubMed ID: 8658983
    [No Abstract]   [Full Text] [Related]  

  • 51. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?
    Kish SJ
    Pharmacol Biochem Behav; 2002 Apr; 71(4):845-55. PubMed ID: 11888575
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Toxicity of drug abuse--amphetamine designer drugs (ecstasy): mental effects and consequences of single dose use.
    Mørland J
    Toxicol Lett; 2000 Mar; 112-113():147-52. PubMed ID: 10720724
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 'Ecstasy' and the use of sleep medications in a general community sample: a 4-year follow-up.
    Tait RJ; George A; Olesen S
    Addiction; 2013 Sep; 108(9):1640-8. PubMed ID: 23651221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The content of ecstasy tablets: implications for the study of their long-term effects.
    Cole JC; Bailey M; Sumnall HR; Wagstaff GF; King LA
    Addiction; 2002 Dec; 97(12):1531-6. PubMed ID: 12472637
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 3,4-methylenedioxymethamphetamine (MDMA): a review.
    O'Leary G; Nargiso J; Weiss RD
    Curr Psychiatry Rep; 2001 Dec; 3(6):477-83. PubMed ID: 11707161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.
    Parrott AC; Buchanan T; Heffernan TM; Scholey A; Ling J; Rodgers J
    Psychopharmacology (Berl); 2003 Jun; 167(4):449-50. PubMed ID: 12682712
    [No Abstract]   [Full Text] [Related]  

  • 57. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome.
    Demirkiran M; Jankovic J; Dean JM
    Clin Neuropharmacol; 1996 Apr; 19(2):157-64. PubMed ID: 8777769
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Toxic effect of MDMA on brain serotonin neurons.
    Morgan JF
    Lancet; 1999 Apr; 353(9160):1268-9; author reply 1270-1. PubMed ID: 10217102
    [No Abstract]   [Full Text] [Related]  

  • 59. Neuropsychiatric manifestations following the use of 3,4-methylenedioxymethamphetamine (MDMA: "Ecstasy").
    Cohen RS; Cocores J
    Prog Neuropsychopharmacol Biol Psychiatry; 1997 May; 21(4):727-34. PubMed ID: 9194153
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Neuroleptic malignant syndrome-dopamine-serotonin syndrome--the physiopathology, diagnosis, and therapy].
    Naito Y
    Seishin Shinkeigaku Zasshi; 1997; 99(10):803-8. PubMed ID: 9465737
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.